Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16265316 | 0.91 | CYP3A4 (0.35) | APPNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL20806200 | 0.88 | NR1H4 (0.41) | APPNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL22299394 | 0.88 | RAB9A (0.41) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL18418540 | 0.85 | APP (0.37) | APPNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL21537514 | 0.82 | — | — | |
| SCHEMBL2572427 | 0.81 | APP (0.48) | APPNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL22298999 | 0.81 | NR1H4 (0.38) | APPNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL22299739 | 0.81 | MAPT (0.36) | APPNPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL17835290 | 0.81 | — | — | |
| SCHEMBL16265318 | 0.81 | SMN1; SMN2 (0.31) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230053362-A1 | DICHROIC DYE COMPOSITION | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11015123-B2 | Liquid-crystal material | MERCK PATENT GMBH (DE) | 2021-05-25 | — | — | US | disclosed |
| US-20200255741-A1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-08-13 | — | — | US | disclosed |
| WO-2020158038-A1 | LIQUID CRYSTAL COMPOSITE AND LIQUID CRYSTAL DIMMER ELEMENT | JNC株式会社 | 2020-08-06 | — | — | WO | disclosed |
| US-10723950-B2 | Liquid-crystalline mixtures | MERCK PATENT GMBH (DE) | 2020-07-28 | — | — | US | disclosed |
| EP-3458549-B1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-10364356-B2 | Device for regulating the passage of energy | MERCK PATENT GMBH (DE) | 2019-07-30 | — | — | US | disclosed |
| US-10260001-B2 | Liquid crystal material | MERCK PATENT GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| US-20190016955-A1 | LIQUID-CRYSTALLINE MIXTURES | MERCK PATENT GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| WO-2017198637-A1 | LIQUID-CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017118464-A1 | LIQUID-CRYSTALLINE MIXTURES | MERCK PATENT GMBH (DE) | 2017-07-13 | — | — | WO | disclosed |
| US-20170029702-A1 | LIQUID CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-02-02 | — | — | US | disclosed |
| US-20170029702-A1 | LIQUID CRYSTAL MATERIAL | MERCK PATENT GMBH (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2016091345-A1 | DEVICE FOR CONTROLLING THE PASSAGE OF ENERGY | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364356-B2 | Device for regulating the passage of energy | MTREX, SLC25A1, TXN2 | APP 2208/4885NPC1 1459/4885ALDH1A1 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.